ThermoGenesis and ImmuneCyte’s Rapid COVID-19 Testing Kit Featured on Local CBS News Titled: “Different Kind of Coronavirus Test”

RANCHO CORDOVA, Calif., April 3, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that it was featured on a CBS 13 news segment titled, “Different Kind of Coronavirus Test”, regarding the Company’s SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit … Continued

ThermoGenesis’ Rapid COVID-19 Serological Test Kit Featured on FOX40 News Story Titled: “Rancho Cordova Company Develops Antibody Test to Detect COVID-19 in Minutes”

ThermoGenesis’ Rapid COVID-19 Serological Test Kit Featured on FOX40 News Story Titled: “Rancho Cordova Company Develops Antibody Test to Detect COVID-19 in Minutes”  RANCHO CORDOVA, Calif., April 2, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that it was … Continued

ThermoGenesis Announces that it has Notified the FDA of its Intent to Distribute the Company’s Rapid COVID-19 Point-of-Care Test Kit

ThermoGenesis Announces that it has Notified the FDA of its Intent to Distribute the Company’s Rapid COVID-19 Point-of-Care Test Kit RANCHO CORDOVA, Calif., March 31, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that it has notified the U.S. Food … Continued

ThermoGenesis Holdings Announces $3.5 Million Registered Direct Offering Priced At-the-Market

RANCHO CORDOVA, Calif., March 25, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 1,000,002 shares of the company’s common … Continued

ThermoGenesis Holdings to Announce Financial Results for the Year Ended December 31, 2019 and Provide a Corporate Strategic Update

Conference Call to be Held on March 24, 2020 RANCHO CORDOVA, Calif., March 18, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the year ended December 31, 2019 and … Continued

ThermoGenesis Holdings Announces Partial Conversion of Revolving Credit Agreement Held by Boyalife Asset Holding II

$3.0 Million of Outstanding Balance Converted into Common Stock RANCHO CORDOVA, Calif., February 19, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that on February 13, 2020, the Company received notice from Boyalife Asset Holding II, Inc. to … Continued

ThermoGenesis Holdings Announces That ImmuneCyte Joint Venture Receives $3.0 Million Equity Investment

RANCHO CORDOVA, Calif., Jan. 3, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that ImmuneCyte Life Sciences, Inc. (“ImmuneCyte”), an 80/20 joint venture between HealthBanks Biotech (USA) and ThermoGenesis, has closed a $3.0 million equity investment with … Continued

© 2020 ThermoGenesis Corp.
How may we help?